pexidartinib + radiation therapy + androgen deprivation therapy

Plexxikon MOA pexidartinib-radiation-androgen

Targeted Indication Status Sites link to clinicaltrials.gov

Prostate Cancer

Phase 1/2a

Detroit, MI

NCT02472275

These compounds and/or uses are investigational and have not been approved by the FDA or any other regulatory authority for the uses under investigation. Image above depicts proposed targeted pathway of the investigational agent(s) in the targeted indication.

Zhu Y et al. Cancer Research. 2014; 74(18); 5057-69. Escamilla J et al. Cancer Research. 2015; 75(6); 950-62.